TheraTech deal

Syntex Corp. has decided to discontinue joint development of the ketorolac transdermal patch. According to THRT, the pharma company based its decision on its risk-assessment profile of the product, which was in Phase II trials for pain control, and its potential commercial viability.

The decision doesn't affect the other potential products in the companies' multi-product agreement, which covers the reproductive physiology and inflammation/pain markets. ...